社区获得性肺炎抗菌药物治疗的临床观察

发布时间：2019-01-24 22:12

【摘要】：目的对比观察莫西沙星、左氧氟沙星和头孢哌酮/舒巴坦在社区获得性肺炎抗感染治疗中的临床疗效及安全性,以降低感染率。方法将180例社区获得性肺炎患者随机分成A、B、C 3组,每组各60例,分别给予莫西沙星、左氧氟沙星、头孢哌酮/舒巴坦静脉滴注治疗,比较3组的临床疗效及安全性。结果 3组的总有效率分别为95.00%、80.00%和78.33%,3组比较差异有统计学意义(P0.05),莫西沙星组的总有效率高于左氧氟沙星组(χ2=6.17,P0.05)及头孢哌酮/舒巴坦组(χ2=7.21,P0.05);3组的细菌清除率分别为93.33%、74.42%和70.45%,3组比较差异有统计学意义(P0.05),莫西沙星组的细菌清除率均高于其余两组,差异均有统计学意义(P0.05),不良反应发生率分别为5.00%、8.33%和6.67%,3组比较差异无统计学意义。结论莫西沙星治疗社区获得性肺炎安全、有效,值得临床推广应用。
[Abstract]:Objective to compare the efficacy and safety of moxifloxacin, levofloxacin and cefoperazone / sulbactam in the treatment of community-acquired pneumonia. Methods 180 patients with community-acquired pneumonia were randomly divided into three groups (n = 60 in each group) and treated with moxifloxacin, levofloxacin and cefoperazone / sulbactam intravenously. The clinical efficacy and safety of the three groups were compared. Results the total effective rates of the three groups were 95.00% and 78.33%, respectively (P0.05). The total effective rate of moxifloxacin group was higher than that of levofloxacin group (蠂 2 6.17, P < 0.05). In cefoperazone / sulbactam group (蠂 2: 7.21 P 0.05) and cefoperazone / sulbactam group (P 0.05); The bacterial clearance rates of the three groups were 93.33% and 70.45%, respectively (P0.05). The bacterial clearance rates of the moxifloxacin group were higher than those of the other two groups. The differences were statistically significant (P0.05), the incidence of adverse reactions were 5.00% and 6.67%, respectively. Conclusion moxifloxacin is safe and effective in the treatment of community-acquired pneumonia.
【作者单位】：天津医院急诊科;
【基金】：天津市医药卫生重点学科攻关基金项目(10KG118)
【分类号】：R563.1

【参考文献】